UK industry to battle QALY reduction and generics price comparisons
This article was originally published in Scrip
Executive Summary
On the eve of a meeting updating its members about its drug pricing negotiations with the UK government, the Association of the British Pharmaceutical Industry Association is pushing hard against the introduction of a value-based pricing system, according to further industry sources who declined to be named. And it may be fighting against plans that threaten drug prices across the board stemming from a potential reduction in the value ascribed to the QALY.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.